This triple-action mechanism distinguishes it from existing approved agents such as semaglutide (a GLP-1 receptor agonist, approved in the UK as Wegovy and Ozempic) and tirzepatide (a dual GIP/GLP-1 receptor agonist, approved as Mounjaro), and is being studied primarily for obesity and type 2 diabetes management
As we discussed above we are careful in our progression to try to minimize side effects
Heres the key shift: Fat tissue isnt just storage, its an active organ that can influence hormones, inflammation, metabolism, and even mood and brain function
Our providers will review your current medications to ensure safe use of Semaglutide
Based on data from similar drugs, weight regain after stopping is significant
And dont forget to celebrate your progress along the way